NasdaqGM:XOMA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	38	-5	N/A	N/A	3
12/31/2025	27	-16	N/A	N/A	3
12/31/2024	21	-22	N/A	N/A	3
3/31/2024	6	-45	-13	-18	N/A
12/31/2023	5	-46	-18	-18	N/A
9/30/2023	4	-32	-18	-18	N/A
6/30/2023	4	-31	-20	-20	N/A
3/31/2023	3	-30	-14	-17	N/A
12/31/2022	6	-23	-13	-13	N/A
9/30/2022	40	10	42	22	N/A
6/30/2022	41	10	36	22	N/A
3/31/2022	41	12	36	23	N/A
12/31/2021	38	8	23	23	N/A
9/30/2021	30	1	-11	10	N/A
6/30/2021	29	6	-3	10	N/A
3/31/2021	29	6	-2	11	N/A
12/31/2020	29	9	10	10	N/A
9/30/2020	2	-13	-12	-12	N/A
6/30/2020	11	-9	-18	-5	N/A
3/31/2020	11	-10	-25	-6	N/A
12/31/2019	18	-2	-20	0	N/A
9/30/2019	20	-2	-18	1	N/A
6/30/2019	12	-8	-27	-5	N/A
3/31/2019	13	-6	-21	-6	N/A
12/31/2018	5	-13	-28	-13	N/A
9/30/2018	9	-11	-30	-15	N/A
6/30/2018	44	9	18	18	N/A
3/31/2018	53	18	13	13	N/A
12/31/2017	53	6	N/A	3	N/A
9/30/2017	48	-11	N/A	15	N/A
6/30/2017	12	-39	N/A	-28	N/A
3/31/2017	2	-61	N/A	-32	N/A
12/31/2016	6	-54	N/A	-34	N/A
9/30/2016	53	-11	N/A	-12	N/A
6/30/2016	55	1	N/A	-19	N/A
3/31/2016	57	-7	N/A	-23	N/A
12/31/2015	55	-21	N/A	-31	N/A
9/30/2015	12	-53	N/A	-77	N/A
6/30/2015	15	-67	N/A	-74	N/A
3/31/2015	18	-55	N/A	-74	N/A
12/31/2014	19	-38	N/A	-78	N/A
9/30/2014	27	-83	N/A	-68	N/A
6/30/2014	28	-99	N/A	-65	N/A
3/31/2014	29	-104	N/A	-60	N/A
12/31/2013	35	-124	N/A	-46	N/A
9/30/2013	30	-69	N/A	-50	N/A
6/30/2013	31	-67	N/A	-48	N/A

アナリストによる今後の成長予測

収入対貯蓄率: XOMA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: XOMA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: XOMA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: XOMAの収益 ( 37.8% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: XOMAの収益 ( 37.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: XOMAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

XOMA 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 64%

Consensus revenue estimates fall by 58%

Consensus revenue estimates fall by 33%

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Recent updates

Consensus revenue estimates increase by 64%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 58%

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 33%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Investor sentiment deteriorated over the past week

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

Investor sentiment improved over the past week

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 12%

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$62.50

Now 24% undervalued

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Now 20% undervalued

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to US$49.00

Price target decreased to US$46.00

Investor sentiment deteriorated over the past week

Xoma Gets The Spotlight

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall to US$9.98m

Consensus EPS estimates increase to -US$0.83

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

Price target increased to US$52.33

CEO & Director recently sold US$303k worth of stock

Investor sentiment improved over the past week

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Consensus EPS estimates fall to -US$1.00

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

XOMA EPS misses by $0.55, misses on revenue

XOMA gets milestone payment from Janssen Biotech

Investor sentiment improved over the past week

Key Executive exercised options to buy US$212k worth of stock.

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Consensus revenue estimates increase to US$17.1m